Compare Domino's Pizza, Inc. (DPZ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Organon & Co. Common Stock — how do they compare? Domino's Pizza, Inc. trades at $298 (market cap $9.74B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Domino's Pizza, Inc. is far larger — about 2.7× Organon & Co. Common Stock's market cap, and Domino's Pizza, Inc. pays the higher dividend (2.69%). Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Organon & Co. Common Stock for 0 Days on average.
| DPZ | OGN | |
|---|---|---|
Market Cap | $9.74B | $3.61B |
Volume | 2,053,142 | 1,808,049 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $13.81 |
52-Week Low | $282.89 | $5.70 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $14.63B | $11.03B |
Dividend Yield | 2.69% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $295.89, down 4.83% with mixed technical signals but strong fundamentals. The stock shows a bullish overall technical signal despite recent price weakness, while fundamentals reveal consistent revenue growth to $4.94 billion in 2025 and healthy net margins of 11.86%. Recent earnings show improvement with a Q3 2026 beat after three consecutive misses, though the company faces high debt levels and flat dividend growth.
The outlook remains cautiously optimistic with a $368 consensus price target representing 24% upside potential. Key opportunities include sustained profitability and market leadership, while risks center on high leverage and competitive pressures. Analyst sentiment leans bullish with 50% buy ratings, but investors should monitor debt management and same-store sales trends.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
